179 related articles for article (PubMed ID: 35757853)
21. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single-Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate.
Paccaly AJ; Kovalenko P; Parrino J; Boyapati A; Xu C; van Hoogstraten H; Ishii T; Davis JD; DiCioccio AT
J Clin Pharmacol; 2021 Jan; 61(1):90-104. PubMed ID: 32726514
[TBL] [Abstract][Full Text] [Related]
22. Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis.
Lamb YN; Deeks ED
Drugs; 2018 Jun; 78(9):929-940. PubMed ID: 29931592
[TBL] [Abstract][Full Text] [Related]
23. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
[TBL] [Abstract][Full Text] [Related]
24. Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection.
Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2019; 13():57-70. PubMed ID: 30587928
[TBL] [Abstract][Full Text] [Related]
25. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
[TBL] [Abstract][Full Text] [Related]
26. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
[TBL] [Abstract][Full Text] [Related]
27. Update of sarilumb to treat rheumatoid arthritis based on randomized clinical trials: a systematic review.
Aly AM; Furst DE
Expert Rev Clin Immunol; 2017 Aug; 13(8):741-752. PubMed ID: 28689441
[TBL] [Abstract][Full Text] [Related]
28. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
Emery P; Rondon J; Parrino J; Lin Y; Pena-Rossi C; van Hoogstraten H; Graham NMH; Liu N; Paccaly A; Wu R; Spindler A
Rheumatology (Oxford); 2019 May; 58(5):849-858. PubMed ID: 30590833
[TBL] [Abstract][Full Text] [Related]
30. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R; van Adelsberg J; Lin Y; Castelar-Pinheiro GD; Brzezicki J; Hrycaj P; Graham NM; van Hoogstraten H; Bauer D; Burmester GR
Arthritis Rheumatol; 2017 Feb; 69(2):277-290. PubMed ID: 27860410
[TBL] [Abstract][Full Text] [Related]
31. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials.
Tanaka Y; Takahashi T; Sumi M; Hagino O; Van Hoogstraten H; Xu C; Kato N; Kameda H
Mod Rheumatol; 2022 Jul; 32(4):686-695. PubMed ID: 34915576
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, pharmacodynamics, and safety of single-dose subcutaneous sarilumab with or without methotrexate in Japanese patients with rheumatoid arthritis: Two single-dose studies.
Ishii T; Sato Y; Munakata Y; Kajiwara M; Takahashi Y; van Hoogstraten H; Xu C; Kato N; Takahashi T
Mod Rheumatol; 2023 Mar; 33(2):279-291. PubMed ID: 35445719
[TBL] [Abstract][Full Text] [Related]
34. Non-Medical Switching from Tocilizumab to Sarilumab in Rheumatoid Arthritis Patients with Low Disease Activity, an Observational Study.
den Broeder N; den Broeder AA; Verhoef LM; van den Hoogen FHJ; van der Maas A; van den Bemt BJF
Clin Pharmacol Ther; 2023 Oct; 114(4):810-814. PubMed ID: 37429827
[TBL] [Abstract][Full Text] [Related]
35. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?
Avci AB; Feist E; Burmester GR
BioDrugs; 2024 Jan; 38(1):61-71. PubMed ID: 37989892
[TBL] [Abstract][Full Text] [Related]
36. The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
Narazaki M; Tanaka T; Kishimoto T
Expert Rev Clin Immunol; 2017 Jun; 13(6):535-551. PubMed ID: 28494214
[TBL] [Abstract][Full Text] [Related]
37. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
38. Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors.
Fleischmann R; Genovese MC; Maslova K; Leher H; Praestgaard A; Burmester GR
Rheumatology (Oxford); 2021 Nov; 60(11):4991-5001. PubMed ID: 33871596
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy.
Song SN; Yoshizaki K
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):307-16. PubMed ID: 25491492
[TBL] [Abstract][Full Text] [Related]
40. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
